Skip to content

US · RPRX · MEDICAL - PHARMACEUTICALS

Royalty Pharma plc (RPRX) intrinsic value and stock valuation

$68.45as of 2026-11-21 · Mkt cap 24.84B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Royalty Pharma plc DCF and intrinsic value

InvestorsCraft values RPRX with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from RPRX’s statements →

Royalty Pharma plc Graham Number

Graham Number: $30.06d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals New York, NY 10022 royaltypharma.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$2.38B+2.3% 5y CAGRd
20152025
Net income
$771M-4.6% 5y CAGRd
20152025
Free cash flow
$2.49B+4.1% 5y CAGRd
20172025
Total equity
$9.71B-0.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B
Operating income$1.56B$1.29B$1.49B$307.1M$1.43B
Net income$771M$859M$1.13B$42.8M$619.7M
EPSd$1.38M$1.45M$1.88M$75.8K$1.49M
Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
Total assets$19.6B$18.2B$16.4B$16.8B$17.5B
Total debt$8.95B$7.61B$6.14B$7.12B$7.1B
Net debt$8.33B$6.68B$5.66B$5.41B$5.56B
Total equity$9.71B$10.3B$10.1B$9.53B$10.2B
Cash and short-term investments$637.5M$1.77B$1.23B$2.43B$2.8B
Income statement
20252024202320222021
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$2.38B$2.26B$2.35B$2.24B$2.29B
Research and development expenses$452M$2M$52M$177.1M$200.1M
Selling, general and administrative expenses$573.5M$236.7M$249.8M$227.3M$182.8M
Other expenses-$-206.81M$732.5M$560.7M$1.53B$475.8M
Operating expenses$818.7M$971.1M$862.4M$1.93B$858.8M
Cost and expenses$818.7M$971.1M$862.4M$1.93B$858.8M
Interest income$33.6M$47.3M$72.3M$78.3M$53.5M
Interest expense$307.7M$225.5M$187.2M$188M$166.1M
Depreciation and amortization$3.85M$0.00$0.00$5.67M$23M
Ebitda$1.64B$1.56B$1.89B$423.7M$1.43B
Operating income$1.56B$1.29B$1.49B$307.1M$1.43B
Total other income/expenses, net-$-235.33M$38.4M$207.9M-$-77M-$-189.51M
Income before tax$1.32B$1.33B$1.7B$230.1M$1.24B
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$771M$859M$1.13B$42.8M$619.7M
Weighted average shares outstanding$431.9M$446M$447.6M$438M$414.8M
Weighted average diluted shares outstanding$559.6M$594M$602.9M$564.9M$414.8M
Balance sheet
20252024202320222021
Cash and short-term investments$637.5M$1.77B$1.23B$2.43B$2.8B
Net receivables$883.7M$27M$22.4M$36.6M$68.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$619M$1.8B$1.27B$2.55B$2.88B
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$924.6M$15.1B$0.00$0.00$5.67M
Long-term investments$171.3M$16.4B$15.1B$14.2B$14.6B
Total non-current assets$17.1B$16.4B$15.1B$14.3B$14.6B
Total assets$19.6B$18.2B$16.4B$16.8B$17.5B
Accounts payable$19.4M$13.4M$15.2M$7.91M$5.62M
Short-term debt$380M$997.8M$0.00$997.5M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$636.2M$1.25B$161.4M$1.17B$171.3M
Long-term debt$8.59B$6.61B$6.14B$6.12B$7.1B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.27B$6.63B$6.14B$6.12B$7.1B
Capital lease obligations$16.1M$0.00$0.00$0.00$0.00
Total liabilities$9.91B$7.88B$6.3B$7.29B$7.27B
Common stock$110K$110K$110K$110K$110K
Retained earnings$2.36B$2.85B$2.52B$1.96B$2.26B
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$16.5M
Total equity$9.71B$10.3B$10.1B$9.53B$10.2B
Total investments$190.1M$17.2B$15.9B$14.9B$15.9B
Total debt$8.95B$7.61B$6.14B$7.12B$7.1B
Net debt$8.33B$6.68B$5.66B$5.41B$5.56B
Cash flow statement
20252024202320222021
Net income$1.32B$1.33B$1.7B$230.1M$1.24B
Depreciation and amortization$3.85M$0.00$0.00$5.67M$23M
Stock-based compensation$289.9M$2.34M$2.36M$2.17M$2.44M
Change in working capital-$-17.15M$53.4M$5.38M$32.7M-$-16.32M
Accounts receivable-$-2.36M-$-4.55M-$-1.52M-$-4.74M-$-29.14M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-13.93M-$-2.29M$6.24M$2.29M-$-4.59M
Net cash provided by operating activities$2.49B$2.77B$2.99B$2.14B$2.02B
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net-$-74.42M-$-10.96M-$-12.54M-$-9.9M-$-34.85M
Net cash used for investing activities-$-1.61B-$-2.68B-$-2.07B-$-1.03B-$-1.87B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-1.23B-$-229.65M-$-304.76M$0.00$0.00
Dividends paid-$-378.25M-$-376.46M-$-358.33M-$-333.32M-$-285.18M
Net cash used for financing activities-$-1.19B$361.1M-$-2.15B-$-944.86M$385.1M
Net change in cash-$-310.33M$452M-$-1.23B$169.7M$532.4M
Cash at end of period$618.7M$929M$477M$1.71B$1.54B
Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Royalty Pharma plc

        Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

        CEO
        Pablo Legorreta
        Employees
        100
        Beta
        0.42

        Explore

        Frequently asked questions

        What is the intrinsic value of Royalty Pharma plc (RPRX)?

        Royalty Pharma plc (RPRX) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RPRX undervalued?

        RPRX trades at a price of $68.45 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.